Educational Intervention Aids Problematic Hypoglycemia

Share this content:
Educational Intervention Aids Problematic Hypoglycemia
Educational Intervention Aids Problematic Hypoglycemia

TUESDAY, Nov. 1, 2016 (HealthDay News) -- A brief, partly web-based educational intervention, HypoAware, is beneficial for reducing severe hypoglycemic episodes and improving hypoglycemia awareness compared with usual care, according to a study published online Oct. 20 in Diabetes Care.

Stefanie M.P.A. Rondags, from the VU University Medical Center in Amsterdam, and colleagues enrolled 137 insulin-treated patients with problematic hypoglycemia in eight Dutch clinics to compare HypoAware care with usual care. The authors assessed self-reported severe hypoglycemia, impaired hypoglycemia awareness, and worries and distress about hypoglycemia at baseline and at two, four, and six months of follow-up.

The researchers found that, compared with the control group, the HypoAware group had 33 percent fewer episodes of severe hypoglycemia (relative risk [RR], 0.67; 95 percent confidence interval [CI], 0.39 to 1.16). They also had significantly reduced odds of impaired awareness (odds ratio, 0.38; 95 percent CI, 0.15 to 0.95), a trend toward fewer worries about hypoglycemia (RR, 0.80; 95 percent CI, 0.64 to 1.01), and a significant reduction in hypo-distress (RR, 0.70; 95 percent CI, 0.56 to 0.88). Participants experienced a median of 2.5 events of severe hypoglycemia in the control condition versus one event in the HypoAware event over the six-month study duration (P = 0.030).

"HypoAware resulted in fewer severe hypoglycemic episodes, significantly improved hypoglycemia awareness, and less hypo-distress in comparison with usual care, and deserves further dissemination," the authors write.

The study was partially funded by Novo Nordisk and Agis Achmea, a Dutch health care insurer.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »